Skip to main content

Table 2 Comparison of the incidence of major drug-related grade 3 or 4 AEs between groups at final follow-up

From: Cetuximab versus bevacizumab following prior FOLFOXIRI and bevacizumab in postmenopausal women with advanced KRAS and BRAF wild-type colorectal cancer: a retrospective study

AEs, n (%) CET (n=100) BEV (n=104) P-value
Skin 21 (21.0) 5 (4.8) 0.001*
Diarrhoea 13 (13.0) 4 (5.4) 0.018*
Anorexia 5 (5.0) 1 (1.0) 0.088
Vomiting 7 (7.0) 1 (1.0) 0.026*
Stomatitis 5 (5.0) 3 (2.9) 0.436
Fatigue 9 (9.0) 2 (1.9) 0.025*
Thrombocytopenia 13 (13.0) 4 (3.8) 0.018*
Dysphonia 3 (3.0) 4 (3.8) 0.740
Proteinuria 10 (10.0) 3 (2.9) 0.038*
Nausea 8 (8.0) 2 (1.9) 0.044*
Hypoalbuminemia 8 (8.0) 7 (6.7) 0.728
Peripheral oedema 7 (7.0) 8 (7.7) 0.850
Hepatic encephalopathy 3 (3.0) 5 (4.8) 0.506
≥ 2 AEs in one patient 23 (22.0) 12 (11.5) 0.030*
  1. *Statistically significant. AEs Adverse events, CET Cetuximab, BEV Bevacizumab